Last reviewed · How we verify
Maribavir Commercial Tablet Formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Maribavir Commercial Tablet Formulation (Maribavir Commercial Tablet Formulation) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Maribavir Commercial Tablet Formulation TARGET | Maribavir Commercial Tablet Formulation | Takeda | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Maribavir Commercial Tablet Formulation CI watch — RSS
- Maribavir Commercial Tablet Formulation CI watch — Atom
- Maribavir Commercial Tablet Formulation CI watch — JSON
- Maribavir Commercial Tablet Formulation alone — RSS
Cite this brief
Drug Landscape (2026). Maribavir Commercial Tablet Formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/maribavir-commercial-tablet-formulation. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab